

Chemomab Therapeutics to Present at September 2024 Investor Conferences

TEL AVIV, Israel — August 28, 2024 — Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that Chief Executive Officer Dr. Adi Mor will deliver corporate presentations at the H.C. Wainwright 26th Annual Global Investment Conference and at the HBM Biopharma Summit 2024. Dr. Mor's prerecorded H.C. Wainwright presentation will be webcast and is available starting on September 9, 2024 at 7:00 am ET. The link to access the webcast is included below and is also available at the [Events section](#) of the Chemomab website. Dr. Mor's live presentation at the HBM Biopharma Summit is scheduled for September 23, 2024. This conference is by invitation only and company presentations will not be webcast.

Chemomab Presentation at 2024 H.C. Wainwright 26th Annual Global Investment Conference

Date: September 9, 2024

Time: Available starting at 7:00 am ET for 90 days

Venue: Virtual

Format: Prerecorded webcast presentation

Webcast Link: <https://journey.ct.events/view/62306e1b-1dae-4bbf-b114-6eaff1f09ae8>

About Chemomab Therapeutics Ltd.

Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody that neutralizes CCL24 activity. In clinical and preclinical studies, CM-101 has been shown to have a favorable safety profile and has been generally well-tolerated to date, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported positive results from four clinical trials of CM-101 in patients, including a Phase 2 trial in patients with primary sclerosing cholangitis (PSC), a Phase 2a liver fibrosis trial in patients with metabolic dysfunction-associated steatohepatitis (MASH), a Phase 1b study in patients with metabolic dysfunction-associated fatty liver disease (MAFLD) and an investigator-initiated study in patients with severe lung injury. Chemomab's CM-101 program for the treatment of systemic sclerosis is Phase 2-ready with an open U.S. IND. For more information, visit www.chemomab.com.

Contacts:

Media and Investors:

Barbara Lindheim

Consulting Vice President, Investor & Public Relations,

Strategic Communications

Phone: +1 917-355-9234

barbara.lindheim@chemomab.com

IR@chemomab.com
